WuXi AppTec Co., Ltd. (WUXIF) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Diagnostics & Research secteur d'activité. Le siège social de l'entreprise est situé à Shanghai, China. Le PDG actuel est Ge Li.
WUXIF a date d'introduction en bourse 2020-03-17, 39,414 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $41.41B.
WuXi AppTec Co., Ltd. is a leading contract research, development, and manufacturing organization headquartered in Shanghai, China. The company provides comprehensive services across the drug development lifecycle, including discovery, preclinical testing, clinical trials, and commercial manufacturing for small molecule drugs, biologics, and cell and gene therapies. Operating through six business segments—WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and others—the company serves pharmaceutical and biotech customers globally across China, Asia, the United States, Europe, and international markets. Founded in 2000, WuXi AppTec has established itself as an integrated solution provider that supports clients from early-stage drug discovery through commercialization across multiple therapeutic modalities.
